The price of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) over the past year has decreased -9.84% while the S&P 500 has increased 19.09%. During the past 20 days, SCMP has increased 32.71% while the broad market has increased 1.68%. SCMP ‘s 20-day moving average currently sits below its 100-day moving average. This is a bearish signal that suggests the stock price might have farther to fall. SCMP’s average trading volume during the past 20 days is lower than the average volume over the past 100 days, which could be an indication that investors are feeling less certain than usual about the direction of SCMP’s future price movements.
Recent trading patterns in the stock of Sucampo Pharmaceuticals, Inc. (SCMP) have investors on high alert. Many experts agree that the best way to predict future performance is by studying the past. In the cast of SCMP, these trading patterns could have some important implications for future performance. In the most recent quarter, institutional ownership increased by a net of 5.9 million shares, or 18.99%.This is a bullish sign and indicates that institutions are feeling more optimistic about the outlook for SCMP overall.101 holders increased their positions, 62 decreased their positions, and 33 holders held their positions.
Among institutions that increased their positions, 32 were new positions. Among holders that decreased their positions, 15 sold out of the stock Sucampo Pharmaceuticals, Inc.. Insider ownership during the latest quarter decreased by a net of 2 million shares, indicating that SCMP’s key executives are feeling more bearish about the stock than they did three months ago. 4 or 66.67% of the trades during the past quarter were buys, and 2 or 33.33% were sells. This activity represents a continuation of a theme over the past twelve months. Insider ownership during the last year has decreased by a net of 21.06 million shares. 85.71% of insider trades in the last 12 months were buys, and 14.29% were sells.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has a 20-day RSI of 78.36%. According to this momentum indicator, a reading above 70 suggests the stock is entering overbought territory and that the recent uptrend may be about to reverse. The MACD tells a similair story. SCMP’s 9-day MACD currently sits below the 20-day MACD, indicating that SCMP’s upside momentum has decreased during the last three weeks. This suggests that the trend might soon reverse. SCMP’s average trading volatility during the past few weeks is 4.05% higher than the average volatility over the past 100 days. This means that the stock’s daily price swings have been more extreme in recent times compared to the past.
Analysts expect Sucampo Pharmaceuticals, Inc. (SCMP) to generate earnings per share of $1.12 in 2017. This works out to a decrease of -25.83% compared to last year’s earnings. For comparison’s sake, analysts expect the S&P 500 to grow earnings by an average of 12% in 2017. The average investment rating for SCMP on a scale of 1 to 5 (1 being a strong sell and 5 being a strong buy) is a 4.33 or a Moderate Buy. Three months ago, analysts assigned SCMP a 4.60 rating, which implies that analysts have become more pessimistic about the outlook for the stock over the next year.